Adalid Sciences was founded in 2024 with the vision of advancing genomic medicine through breakthrough drug delivery technologies. Since its establishment, the company has focused on discovering and developing novel lipid nanoparticles (LNPs) with exceptional properties for efficient gene delivery. These advanced delivery systems are designed to treat and prevent diseases with urgent and unmet medical needs by enabling precise and effective delivery of genetic material. By combining cutting-edge nanotechnology, pharmaceutical science, and genomic innovation, Adalid Sciences is working to overcome key limitations in existing gene therapy approaches and accelerate the development of next-generation therapeutic solutions that can significantly improve patient outcomes.